The Latest Cardiac and Vascular News
CoSo Health to exclusively distribute Medinol’s most advanced coronary DES in the U.S. DENVER and TEL AVIV, Israel, Oct. 24, 2023 /PRNewswire/ — Medinol today announced United States Food and Drug Administration (FDA) approval for the EluNIR-PERL™ drug-eluting stent (DES) for the…
TEL AVIV, Israel, May 31, 2023 /PRNewswire/ — Valve Medical, a wholly owned subsidiary of Medinol Ltd. is pleased to announce today the successful First-in-Human (FIH) implantation of their advanced Transcatheter Aortic Valve Replacement (TAVR) system in Israel, introducing a revolutionary advancement in Structural Heart procedures with the world’s first modular valve. The Valve Medical Xemed TAVR device […]
N.Y. Presbyterian/Columbia implant EluNIR stent Cordis and Medinol Announce First U.S. Commercial Implants of Innovative EluNIR™ Drug-Eluting Stent – by CardiovascularBusiness DUBLIN, Ohio, January 11, 2018 — Cordis, a Cardinal Health company, and Medinol today announced that the first commercial cases using the EluNIR™ drug-eluting stent (DES) in the United States were performed at New York-Presbyterian […]
DUBLIN, Ohio, Nov. 30, 2017 /PRNewswire/ — Cordis, a Cardinal Health company, and Medinol today announced United States Food and Drug Administration (FDA) approval of the EluNIR™ drug-eluting stent (DES) for the treatment of patients with narrowing or blockages to their coronary arteries. The EluNIR™ stent system is designed with a novel metallic spring tip and the narrowest […]
Medinol, a global Interventional Cardiology device company, announced that it obtained CE-mark for EluNIR™, its novel Drug Eluting Stent featuring a unique stent design with low metal footprint and a proprietary elastomeric coating, both designed to optimize clinical outcomes. EluNIR demonstrated outstanding outcomes in two randomized pivotal studies. In BIONICS, a more-comers study conducted in the United States, Canada, Europe and Israel, […]
